文献速递肺外科

脂质体布比卡因对肺切除ERAS方案的影响

Impact of Liposomal Bupivacaine on Enhanced Recovery After Surgery Protocol for Lung Resection.
PubMed 文献 · Ann Thorac Surg · 2024-05-28

回顾性观察研究比较2015年1月至2021年12月间三组肺叶切除术患者,对照组未用脂质体布比卡因且未行ERAS方案,单用脂质体布比卡因组仅接受神经阻滞,ERAS组接受神经阻滞并行ERAS方案。主要结局为术后阿片类药物消耗量。结果显示脂质体布比卡因单用及联合ERAS方案均显著减少阿片类药物用量,联合ERAS方案减少幅度更大,但住院时间和30天再入院率无显著差异。作者指出需前瞻性研究验证可重复性和适用性。

要点

  • 脂质体布比卡因单用组阿片类药物用量为30.5 OME,低于对照组的43 OME(P < .001)。
  • ERAS联合脂质体布比卡因组阿片类药物用量为17 OME,低于对照组和单用组(P < .001)。
  • 两兴趣组住院时间均为3天,无统计学差异;30天再入院率三组无显著差异(P = .43)。

核心结论

  • 脂质体布比卡因单用作为更大ERAS方案的一部分可显著减少阿片类药物用量和住院时间,但将脂质体布比卡因纳入ERAS方案而非单独使用对阿片类药物用量的减少幅度更大。
  • 需要前瞻性研究来确定脂质体布比卡因减少阿片类药物用量在美国其他医院系统的可重复性和适用性。

研究设计与样本

  • 回顾性观察研究,比较2015年1月至2021年12月期间接受肺叶切除术的三组患者,共433例:对照组87例(术中未接受脂质体布比卡因且未行ERAS方案),单用脂质体布比卡因组138例(仅接受神经阻滞),ERAS/脂质体布比卡因组208例(术中接受神经阻滞并行ERAS方案)。

主要发现

  • 术后阿片类药物消耗量:对照组43 OME vs 单用脂质体布比卡因组30.5 OME(P < .001)。
  • 术后阿片类药物消耗量:对照组43 OME vs ERAS/脂质体布比卡因组17 OME(P < .001)。
  • 术后阿片类药物消耗量:单用脂质体布比卡因组30.5 OME vs ERAS/脂质体布比卡因组17 OME(P < .001)。
  • 住院时间:两兴趣组均为3天,无统计学差异;对照组为4天,与两兴趣组不同。
  • 30天再入院率三组间无显著差异(P = .43)。

临床怎么用

  • 作者结论认为脂质体布比卡因单用作为更大ERAS方案的一部分可显著减少阿片类药物用量和住院时间,但纳入ERAS方案对阿片类药物用量的减少幅度更大。
  • 作者指出需要前瞻性研究来确定脂质体布比卡因减少阿片类药物用量在美国其他医院系统的可重复性和适用性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited data showing the benefit of liposomal bupivacaine as part of an Enhanced Recovery After Surgery (ERAS) protocol in reducing opioid use in minimally invasive lobectomies. METHODS: A retrospective observational study compared 3 cohorts of patients who underwent lobectomies between January 2015 and December 2021. The control group neither received liposomal bupivacaine intraoperatively nor underwent an ERAS protocol. The liposomal bupivacaine cohort only received a nerve block, whereas the ERAS cohort received a nerve block intraoperatively and underwent an ERAS protocol. The primary outcome was postoperative opioid consumption. RESULTS: The study included 433 patients, comprising 87 in the control group, 138 in the liposomal bupivacaine alone cohort, and 208 in the ERAS/liposomal bupivacaine cohort. There was a statistically significant difference in the amount of opioids used between the control (43 oral morphine equivalents [OME]) and liposomal bupivacaine alone cohort (30.5 OME; P < .001), between control vs the ERAS/liposomal bupivacaine cohort (17 OME; P < .001), and between the liposomal bupivacaine alone and ERAS/liposomal bupivacaine cohorts (P < .001). Hospital stay was not statistically different between the 2 groups of interest (3 days); however, hospital stay differed from the control (4 days). Readmission at 30 days was not significantly different between the 3 groups (P = .43). CONCLUSIONS: Liposomal bupivacaine alone as part of a larger ERAS protocol significantly reduced opioid use and hospitalization duration; however, the reduction in opioid use was much greater with incorporation of liposomal bupivacaine into an ERAS protocol rather than in isolation. Prospective studies are needed to determine reproducibility and applicability of liposomal bupivacaine for opioid use reduction in other United States hospital systems.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Bauerle WB, Hamlin S, Dubois S, et al. Impact of Liposomal Bupivacaine on Enhanced Recovery After Surgery Protocol for Lung Resection. Ann Thorac Surg. 2024. PMID: 38815849. doi:10.1016/j.athoracsur.2024.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。